Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis

Figure 3 Relationship between baseline red cell distribution width/platelet ratio values and validated tools non-invasively assessing liver-function status and hepatic fibrosis. A, B, C, E, F, G and H: Linear regression of red cell distribution width to platelet ratio (RPR) and Model for End-Stage Liver Disease (A); RPR and Child-Push score (B); RPR and aspartate aminotransferase/platelet count ratio index (C); RPR and Liver Stiffness Measurement (E); RPR and Fibrosis-4 (FIB-4; F); RPR and Albumin-Bilirubin (ALBI; G); RPR and ALBI/FIB-4 (H). D: Heat map of R values revealed of to the linear regression analysis between baseline RPR others tools reported in panel A, B, C, E, F, G, H. LSM: Liver Stiffness Measurement; ALBI: Albumin-Bilirubin; FIB-4: Fibrosis-4; APRI: Aspartate aminotransferase/platelet count ratio index; MELD: Model for End-Stage Liver Disease; RPR: Red cell distribution width to platelet ratio.